AB1059 POSSIBILITIES OF COMBINED THERAPY FOR TREATMENT OF HYPERURICEMIA AND ARTICULAR SYNDROME EXACERBATIONS IN PATIENTS WITH GOUT

Background Throughout the year 69 per cent of patients with gout experienced repeated exacerbations during therapy aimed at reducing urate levels. Prevention arthritis low-dose NSAIDs should be done in first 3-6 months urate-reducing therapy. Objectives To assess frequency and quality life after a 12 weeks course allopurinol combination anti-inflammatory drug meloxicam for prevention exacerbations. Methods Physical examination, сlinical blood, urine tests, biochemical blood instrumental diagnostics were performed all patients. Information about concomitant diseases was entered, recorded time observation. Allopurinol administered orally, once day. Every 3 under control serum uric acid levels (sUA), dosage increased by 50 mg, up to 300 mg The total daily dose different forms 7.5-15 mg. After 3, 6, 9 weeks, clinical effeciency treatment assessed using EuroQol-5D-5L questionnaire, physical joint pain dynamics rest, movement palpation, as well Likert scale visual analog (VAS) mm. Factors such presence anxiety or depression, self-care ability, normal activities living taken into account, their rating level satisfaction on 1 5, where is not an improvement but deterioration 5 very good result. Both period remission before onset recurrence gouty adverse events (AEs) recorded. Results 143 established diagnosis (ACR/EULAR, 2015) examined outpatient appointment. Against background 7.5 day, more than two-thirds did experience worsening syndrome increase By 12th week follow-up, it found that characteristic features significantly began differ improving mobility, self-care, habitual activities, soreness, depression (p <0.05). Moreover, initial ESR sUA from follow-up endpoint < 0.05), indicating positive effect inflammatory process. A three-month cause significant pressure change creatinine clearance From gastrointestinal tract there no events. 90.9% efficiency good. AEs form allergic skin rash observed one patient. But need interrupt treatment, completely disappeared without consequences completing meloxicam. Conclusion 12-week allopurinol, drug, meloxicam, prevents exacerbation improves gout. Disclosure Interests None declared